Article ID Journal Published Year Pages File Type
2514781 Biochemical Pharmacology 2007 7 Pages PDF
Abstract
We examined the effects of various isozyme-selective PDE inhibitors on HCO3− secretion in the mouse duodenum in vitro and investigated which type(s) of phosphodiesterase (PDE) isozymes are involved in the response to PGE2 and NO. The duodenal mucosa of male DDY mice was stripped of the muscle layer and mounted on an Ussing chamber, and HCO3− secretion was measured at pH 7.0 by a pH-stat method using 2 mM HCl. Both PGE2 and NOR-3 (NO donor) increased HCO3− secretion in the mouse duodenum in vitro, and the response to PGE2 was inhibited by both EP3 and EP4 antagonists but not EP1 antagonist, while that to NOR-3 was inhibited by methylene blue. IBMX, a nonselective PDE inhibitor, significantly increased basal HCO3− secretion and potentiated the responses to both PGE2 and NOR-3. Likewise, vinpocetine (PDE1 inhibitor) and cilostamide (PDE3 inhibitor) also increased the basal secretion at high doses and potentiated the HCO3− response to PGE2 at doses that had no effect by themselves on the basal secretion. By contrast, the HCO3− stimulatory action of NOR-3 was significantly potentiated by vinpocetine but not cilostamide. Inhibitors of other PDE subtypes had no effect on the HCO3− secretion under basal or stimulated conditions. Both PDE1 and PDE3 mRNAs were expressed in the duodenal mucosa. These results suggested that PDE1 and PDE3 are involved in the regulation of duodenal HCO3− secretion and that the response to PGE2 is associated with both PDE1 and PDE3, while the response to NO is mainly modulated by PDE1.
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology
Authors
, , , , ,